Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia

NCT02795520 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

32

Enrollment

INDUSTRY

Sponsor class

Stopped slow patient accrual

Conditions

AML
Advanced MDS
ALL
Advanced CML
Advanced MPNs

Interventions

DRUG: OTS167IV

Sponsor

OncoTherapy Science, Inc.